Corteva (NYSE:CTVA) Raised to Strong-Buy at Zacks Research

Corteva (NYSE:CTVA) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. UBS Group lowered their target price on Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 9th. Weiss Ratings upgraded Corteva from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, May 7th. Oppenheimer upped their price objective on Corteva from $86.00 to $89.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. The Goldman Sachs Group increased their price objective on Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Finally, CICC Research lifted their target price on Corteva from $80.00 to $93.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.95.

Corteva Stock Down 1.3%

Shares of CTVA opened at $84.91 on Monday. The firm has a market cap of $56.79 billion, a P/E ratio of 49.95, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.03 and a current ratio of 1.47. Corteva has a 52 week low of $60.53 and a 52 week high of $87.69. The firm’s 50-day simple moving average is $80.53 and its 200 day simple moving average is $77.87.

Corteva (NYSE:CTVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The firm had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.64 billion. During the same period last year, the business posted $1.13 earnings per share. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts forecast that Corteva will post 3.72 earnings per share for the current year.

Hedge Funds Weigh In On Corteva

A number of hedge funds have recently added to or reduced their stakes in CTVA. Tema ETFs LLC raised its holdings in Corteva by 10.4% in the 2nd quarter. Tema ETFs LLC now owns 10,774 shares of the company’s stock valued at $912,000 after acquiring an additional 1,015 shares in the last quarter. City Holding Co. grew its holdings in shares of Corteva by 2.6% during the 2nd quarter. City Holding Co. now owns 25,086 shares of the company’s stock worth $2,124,000 after purchasing an additional 635 shares in the last quarter. Sax Wealth Advisors LLC acquired a new stake in shares of Corteva during the 2nd quarter worth $237,000. Avity Investment Management Inc. increased its position in shares of Corteva by 14.4% in the second quarter. Avity Investment Management Inc. now owns 5,172 shares of the company’s stock worth $438,000 after purchasing an additional 650 shares during the period. Finally, Valeo Financial Advisors LLC increased its position in shares of Corteva by 8.3% in the second quarter. Valeo Financial Advisors LLC now owns 6,963 shares of the company’s stock worth $589,000 after purchasing an additional 536 shares during the period. Institutional investors own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.